Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants

Next Previous
Trial Profile

A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plozalizumab (Primary)
  • Indications Atherosclerosis; Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Takeda

Most Recent Events

  • 26 Oct 2016 Status changed from discontinued to withdrawn prior to enrolment due to business decision; No Safety or Efficacy Concerns
  • 26 Jul 2016 Status changed from recruiting to discontinued.
  • 19 Nov 2015 Planned End Date changed from 1 Aug 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top